357 related articles for article (PubMed ID: 30783904)
1. Delivery Technologies for Orally Inhaled Products: an Update.
Moon C; Smyth HDC; Watts AB; Williams RO
AAPS PharmSciTech; 2019 Feb; 20(3):117. PubMed ID: 30783904
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary drug delivery by powder aerosols.
Yang MY; Chan JG; Chan HK
J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
[TBL] [Abstract][Full Text] [Related]
3. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
Lin YW; Wong J; Qu L; Chan HK; Zhou QT
Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
[TBL] [Abstract][Full Text] [Related]
4. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
5. Back to the future: inhaled drug products.
Hickey AJ
J Pharm Sci; 2013 Apr; 102(4):1165-72. PubMed ID: 23381932
[TBL] [Abstract][Full Text] [Related]
6. Formulation techniques for high dose dry powders.
Brunaugh AD; Smyth HDC
Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in liposomal dry powder formulations: preparation and evaluation.
Misra A; Jinturkar K; Patel D; Lalani J; Chougule M
Expert Opin Drug Deliv; 2009 Jan; 6(1):71-89. PubMed ID: 19236209
[TBL] [Abstract][Full Text] [Related]
8. Formulation strategy and use of excipients in pulmonary drug delivery.
Pilcer G; Amighi K
Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
[TBL] [Abstract][Full Text] [Related]
9. How can we bring high drug doses to the lung?
Claus S; Weiler C; Schiewe J; Friess W
Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
[TBL] [Abstract][Full Text] [Related]
10. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
11. Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases.
Ferguson GT; Hickey AJ; Dwivedi S
Respir Med; 2018 Jan; 134():16-23. PubMed ID: 29413503
[TBL] [Abstract][Full Text] [Related]
12. Dry powder inhalation: past, present and future.
de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
[TBL] [Abstract][Full Text] [Related]
13. Developing and advancing dry powder inhalation towards enhanced therapeutics.
Stegemann S; Kopp S; Borchard G; Shah VP; Senel S; Dubey R; Urbanetz N; Cittero M; Schoubben A; Hippchen C; Cade D; Fuglsang A; Morais J; Borgström L; Farshi F; Seyfang KH; Hermann R; van de Putte A; Klebovich I; Hincal A
Eur J Pharm Sci; 2013 Jan; 48(1-2):181-94. PubMed ID: 23142635
[TBL] [Abstract][Full Text] [Related]
14. Device factors affecting pulmonary delivery of dry powders.
Smutney CC; Grant M; Kinsey PS
Ther Deliv; 2013 Aug; 4(8):939-49. PubMed ID: 23919473
[TBL] [Abstract][Full Text] [Related]
15. Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers.
Islam N; Richard D
Curr Cancer Drug Targets; 2019; 19(3):162-178. PubMed ID: 29793407
[TBL] [Abstract][Full Text] [Related]
16. Challenges for pulmonary delivery of high powder doses.
Sibum I; Hagedoorn P; de Boer AH; Frijlink HW; Grasmeijer F
Int J Pharm; 2018 Sep; 548(1):325-336. PubMed ID: 29991452
[TBL] [Abstract][Full Text] [Related]
17. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
18. The role of disposable inhalers in pulmonary drug delivery.
de Boer AH; Hagedoorn P
Expert Opin Drug Deliv; 2015 Jan; 12(1):143-57. PubMed ID: 25374325
[TBL] [Abstract][Full Text] [Related]
19. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
[TBL] [Abstract][Full Text] [Related]
20. Advances in device and formulation technologies for pulmonary drug delivery.
Chan JG; Wong J; Zhou QT; Leung SS; Chan HK
AAPS PharmSciTech; 2014 Aug; 15(4):882-97. PubMed ID: 24728868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
